NBS Share Price

Open 2.34 Change Price %
High 2.37 1 Day -0.09 -3.85
Low 2.25 1 Week 0.00 0.00
Close 2.25 1 Month 0.00 0.00
Volume 1117631 1 Year 0.00 0.00
52 Week High 14.87
52 Week Low 12.13
NBS Important Levels
Resistance 2 2.36
Resistance 1 2.32
Pivot 2.29
Support 1 2.18
Support 2 2.14
AMEX USA Most Active Stocks
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
GST 0.94 11.90%
UEC 1.62 15.71%
ROX 1.83 7.65%
ROX 1.83 7.65%
SYN 0.64 -9.86%
SYN 0.64 -9.86%
RBY 0.03 -70.00%
More..
AMEX USA Top Gainers Stocks
GGR 0.02 100.00%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
ATC 0.37 60.87%
MBA 0.20 25.00%
MBA 0.20 25.00%
MBA 0.20 25.00%
IG 7.68 22.49%
IG 7.68 22.49%
More..
AMEX USA Top Losers Stocks
RBY 0.03 -70.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
PAL 0.05 -50.00%
QBC 0.20 -33.33%
ATL 0.06 -25.00%
ATL 0.06 -25.00%
CPHI 0.22 -21.43%
SNT 0.12 -20.00%
INV 0.14 -17.65%
More..

Neostem, Inc. (AMEX: NBS)

NBS Technical Analysis 5
As on 5th Jun 2015 NBS Share Price closed @ 2.25 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.30 & Strong Sell for SHORT-TERM with Stoploss of 2.70 we also expect STOCK to react on Following IMPORTANT LEVELS.
NBS Target for June
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
NBS Other Details
Segment EQ
Market Capital 99785712.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.neostem.com
NBS Address
NBS
420 Lexington Avenue
Suite 450
New York, NY 10170
United States
Phone: 212-584-4180
Fax: 646-514-7787
NBS Latest News
Caladrius Biosciences Closes the Sale of its Remaining Interest in PCT to ...   GlobeNewswire (press release)   - 19th May 17
The Strange Case Of Caladrius Biosciences   Seeking Alpha   - 17th Apr 17
Hitachi Chemical Signs Agreement to Purchase from Caladrius Biosciences the ...   GlobeNewswire (press release)   - 17th Mar 17
Is Caladrius Biosciences Inc. A Buy?   Seeking Alpha   - 10th Mar 17
Caladrius Biosciences Awarded $12.2 Million Grant from CIRM in Support of ...   GlobeNewswire (press release)   - 24th Feb 17
Caladrius Biosciences to Present at Upcoming February Conferences   GlobeNewswire (press release)   - 01st Feb 17
Caladrius Biosciences Needs A Major Strategic Change   Seeking Alpha   - 05th Feb 16
News Caladrius Biosciences Inc.CLBS   Wall Street Journal   - 09th Jun 15
4.18   MarketWatch   - 09th Jun 15
NeoStem Announces Plans to Change Name to Caladrius Biosciences Reflecting ...   GlobeNewswire (press release)   - 29th May 15
Interactive Technical Analysis Chart Neostem, Inc. ( NBS AMEX USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Neostem, Inc.
NBS Business Profile
NeoStem, Inc. develops cell based therapeutics. The company is involved in the manufacture of cell therapy-based products; and provides product and process development, cell and tissue processing, regulatory support, storage, distribution and delivery, and consulting services. It also offers contract development and manufacturing services to clients advancing in the regenerative medicine industry; and collects, processes, and stores umbilical cord blood units and adult stem cells. The company is developing AMR-001, an autologous adult stem cell product to treat damaged heart muscle following an acute myocardial infarction. In addition, it develops T regulatory cell based therapeutics to treat diseases caused by imbalances in the immune system; and researches and develops therapeutics based on very small embryonic-like technology. The company has a collaboration agreement with Becton-Dickinson. NeoStem, Inc. was founded in 1980 and is headquartered in New York, New York.